Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]
Awaiting development
Reference number: GID-TA11019
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2026 when we will write to stakeholders about how they can get involved.